Table 1.
Baseline characteristics of the five trials included for analysis
| Author (year) | Phase | Total patients | Age (years) | Treatment regimens | No for analysis | FAEs | Median PFS (months) | Jadad score |
|---|---|---|---|---|---|---|---|---|
| Leboulleux et al32 (2012) | II | 145 | 63 | Vandetanib 300 mg qd po | 72 | 2 | 11.1 | 5 |
| 64 | Placebo | 73 | 1 | 5.9 | ||||
| Wells et al30 (2012) | III | 331 | 50.7 | Vandetanib 300 mg qd po | 231 | 5 | 30.5 | 5 |
| 53.4 | Placebo | 100 | 2 | 19.3 | ||||
| Elisei et al29 (2013) | III | 330 | 55 | Cabozantinib 140 mg qd po | 214 | 17 | 11.4 | 5 |
| 55 | Placebo | 109 | 8 | 4 | ||||
| Brose et al31 (2014) | III | 416 | 63 | Sorafenib 400 mg bid po | 207 | 12 | 10.8 | 5 |
| 63 | Placebo | 209 | 6 | 5.8 | ||||
| Schlumberger et al33 (2015) | III | 392 | 64 | Lenvatinib 24 mg qd po | 261 | 6 | 18.3 | 5 |
| 61 | Placebo | 131 | 0 | 3.6 |
Abbreviations: bid, twice daily; FAEs, fatal adverse events; PFS, progression-free survival.